Curemark
Rye Brook, US · Delaware LLC · 1 known investors
Curemark is a clinical-stage biopharmaceutical company developing therapies for neuro-developmental and neurodegenerative disorders. Its lead candidate, CM-AT, is a disorder-modifying therapy for Autism.
BiotechHealthtech
Founders & leadership
JF
Joan FallonFounder
MH
Matthew HeilExecutive
KD
Kimball DuncanManager of the LLC
KK
Klaus KleinfeldManager of the LLC
EH
Eric HermanManager of the LLC
Board
LM
Leigh MorganBoard director
KD
Kimbell DuncanBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$62.4M disclosed across 10 rounds · 2012–2023
▶$1.3MraisedMar 2023 · 5 investors · BiotechnologyRule 506(b)
▶$1.3MraisedMar 2023 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kimball DuncanDirector
- Joan FallonExecutive Officer, Director
- Leigh MorganDirector
- Afia AsamoahDirector
- Matthew HeilExecutive Officer
- Offering amount
- $15M
- Amount sold
- $1.3M
- First sale
- Jan 2023
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedApr 2021 · 2 investors · BiotechnologyRule 506(b)
▶$1.5MraisedApr 2021 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Leigh MorganDirector
- Joan FallonExecutive Officer, Director
- Matthew HeilExecutive Officer
- Kimbell DuncanDirector
- Offering amount
- $5M
- Amount sold
- $1.5M
- First sale
- Mar 2021
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$5.4MraisedSep 2019 · 1 investors · BiotechnologyRule 506(b)
▶$5.4MraisedSep 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- KIMBELL DUNCANDirector
- JENNIFER FRISTDirector
- MATTHEW HEILExecutive Officer
- JZANEEN LALANIExecutive Officer
- JOAN FALLONExecutive Officer, Director
- Offering amount
- $50M
- Amount sold
- $5.4M
- First sale
- Aug 2019
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$1.7MraisedApr 2018 · 1 investors · BiotechnologyRule 506(b)
▶$1.7MraisedApr 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jzaneen LalaniExecutive Officer
- Eric HermannDirector
- Jennifer FristDirector
- Matthew HeilExecutive Officer
- Justin StebbingDirector
- Joan FallonExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $1.7M
- Minimum investment
- $1M
- First sale
- Apr 2018
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$3.2MraisedJan 2018 · 1 investors · BiotechnologyRule 506(b)
▶$3.2MraisedJan 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Eric HermannDirector
- Jennifer FristDirector
- Jzaneen LalaniExecutive Officer
- Matthew HeilExecutive Officer
- Joan FallonExecutive Officer, Director
- Justin StebbingDirector
- Offering amount
- $80M
- Amount sold
- $3.2M
- First sale
- Jan 2018
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$3MraisedMar 2017 · 2 investors · BiotechnologyRule 506(b)
▶$3MraisedMar 2017 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew HeilExecutive Officer
- Joan FallonExecutive Officer, Director
- Eric HermannDirector
- Jzaneen LalaniExecutive Officer
- Justin StebbingDirector
- Jennifer FristDirector
- Offering amount
- $150M
- Amount sold
- $3M
- First sale
- Mar 2017
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$20.3MraisedJul 2015 · 2 investors · BiotechnologyRule 506(b)
▶$20.3MraisedJul 2015 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew HeilExecutive Officer
- Kimball DuncanDirector
- Eric HermanDirector
- Joan FallonExecutive Officer, Director
- Offering amount
- $29.5M
- Amount sold
- $20.3M
- Proceeds to insiders
- $800K
- First sale
- Jun 2015
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$5MraisedJan 2015 · 1 investors · BiotechnologyRule 506(b)
▶$5MraisedJan 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kimball DuncanDirector
- Klaus KleinfeldDirector
- Eric HermanDirector
- Matthew HeilExecutive Officer
- Joan FallonExecutive Officer, Director
- Offering amount
- $17.5M
- Amount sold
- $5M
- Minimum investment
- $1M
- Proceeds to insiders
- $1.6M
- First sale
- Dec 2014
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Curemark do?
- Curemark is a clinical-stage biopharmaceutical company developing therapies for neuro-developmental and neurodegenerative disorders. Its lead candidate, CM-AT, is a disorder-modifying therapy for Autism.
- Who founded Curemark?
- Curemark was founded by Joan Fallon.
- Who are Curemark's investors?
- Curemark's investors include Social Impact Capital.
- How much funding has Curemark raised?
- Curemark has disclosed $62.4M raised across 10 rounds.
- Where is Curemark headquartered?
- Curemark is headquartered in Rye Brook, US.